- Home
- CIFR vs LIVN Comparison
CIFR vs LIVN Comparison
Compare CIFR & LIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CIFR
- LIVN
- Stock Information
- Founded
- CIFR 2021
- LIVN 1987
- Country
- CIFR United States
- LIVN United Kingdom
- Employees
- CIFR N/A
- LIVN N/A
- Industry
- CIFR Investment Bankers/Brokers/Service
- LIVN Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CIFR Finance
- LIVN Health Care
- Exchange
- CIFR Nasdaq
- LIVN Nasdaq
- Market Cap
- CIFR 2.1B
- LIVN 2.1B
- IPO Year
- CIFR N/A
- LIVN 1993
- Fundamental
- Price
- CIFR $6.68
- LIVN $44.12
- Analyst Decision
- CIFR Strong Buy
- LIVN Strong Buy
- Analyst Count
- CIFR 11
- LIVN 7
- Target Price
- CIFR $7.58
- LIVN $59.29
- AVG Volume (30 Days)
- CIFR 49.7M
- LIVN 521.7K
- Earning Date
- CIFR 08-07-2025
- LIVN 08-06-2025
- Dividend Yield
- CIFR N/A
- LIVN N/A
- EPS Growth
- CIFR N/A
- LIVN N/A
- EPS
- CIFR N/A
- LIVN N/A
- Revenue
- CIFR $152,092,000.00
- LIVN $1,275,380,000.00
- Revenue This Year
- CIFR $87.55
- LIVN $8.02
- Revenue Next Year
- CIFR $68.51
- LIVN $5.83
- P/E Ratio
- CIFR N/A
- LIVN N/A
- Revenue Growth
- CIFR N/A
- LIVN 7.62
- 52 Week Low
- CIFR $1.86
- LIVN $32.48
- 52 Week High
- CIFR $7.77
- LIVN $57.35
- Technical
- Relative Strength Index (RSI)
- CIFR 69.33
- LIVN 48.77
- Support Level
- CIFR $5.95
- LIVN $41.94
- Resistance Level
- CIFR $7.10
- LIVN $43.46
- Average True Range (ATR)
- CIFR 0.56
- LIVN 1.15
- MACD
- CIFR 0.03
- LIVN -0.28
- Stochastic Oscillator
- CIFR 77.05
- LIVN 39.78
About CIFR Cipher Mining Inc.
Cipher Mining Inc ia an emerging technology company that operates in the Bitcoin mining ecosystem in the United States. The company is developing a cryptocurrency mining business, specializing in Bitcoin. The company is expanding and strengthening the Bitcoin network's critical infrastructure in the United States.
About LIVN LivaNova PLC
UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.